Every 10-Q that OmniAb, Inc. (OABI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OABI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OABI filings page.
OmniAb, Inc. reported a sharp increase in partner-driven revenue while remaining loss-making. For the quarter ended June 30, 2026, total revenue was 13,415 (in thousands), up 244% year over year, led by license and milestone revenue of 9,515 (in thousands) and higher service, xPloration and royalty streams.
Operating expenses were essentially flat at 20,052 (in thousands) as research and development and general and administrative costs declined double digits following 2025 reorganizations, offset by higher amortization. Quarterly net loss narrowed to 5,859 (in thousands) from 15,875 (in thousands). For the first six months, revenue grew 246% to 27,842 (in thousands) while net loss improved to 13,566 (in thousands) from 34,075 (in thousands). Cash used in operating activities fell to $2.2 million from $21.0 million.
Liquidity remains solid, with $52.0 million of cash, cash equivalents and short-term investments as of June 30, 2026, and management states this is sufficient to fund operations for at least 12 months. The balance sheet carries 200,047 (in thousands) of goodwill and intangible assets after a $2.9 million impairment earlier in 2026 on a legacy small-molecule ion channel customer relationship. The partner base continues to expand: 110 active partners supported 425 active programs, including 34 clinical programs and approved products, underscoring the potential for future milestones and royalties.
OmniAb, Inc. reported sharply improved first-quarter 2026 results while remaining unprofitable. Revenue rose to $14.4 million from $4.2 million, driven mainly by a $10.0 million increase in license and milestone revenue. Service, xPloration and royalty revenue also grew modestly.
Operating expenses were broadly flat at $22.3 million, as lower research and development and general and administrative costs offset higher amortization of intangibles, including a $2.9 million impairment of certain legacy ion channel customer relationship assets. Net loss narrowed to $7.7 million from $18.2 million, or $0.06 per share versus $0.17 per share.
OmniAb ended March 31 2026 with $49.1 million in cash, cash equivalents and short-term investments and believes this balance can fund operations for at least the next 12 months. The company continues to scale its antibody discovery platform, with 107 active partners, 409 active programs and 3 approved partnered products.
OmniAb, Inc. reported Q3 2025 results showing lower revenue and continued investment in its platform. Total revenue was $2.239 million (vs. $4.172 million a year ago), and net loss was $16.525 million, or $0.14 per share. For the nine months, revenue was $10.290 million and net loss was $50.600 million.
On the balance sheet, cash and cash equivalents were $28.537 million and short‑term investments were $30.963 million as of September 30, 2025. Operating cash used was $30.781 million for the nine months. Shares outstanding were 143,955,400 as of October 28, 2025.
To support operations, OmniAb completed an August 2025 private placement of 21,254,106 shares at $1.40 (or $1.85 for certain insiders) for approximately $30.0 million in gross proceeds; the resale registration became effective on September 19, 2025. The company also recorded a $3.0 million gain from the sale of an ion channel asset in May 2025.
OmniAb, Inc. (OABI) Q2 2025 condensed summary. Total revenue was $3.897 million for the three months ended June 30, 2025 versus $7.614 million in Q2 2024. Net loss was $15.875 million in Q2 2025 versus $13.631 million in Q2 2024; six-month net loss was $34.075 million versus $32.592 million prior-year. Cash and cash equivalents declined to $18.281 million and short-term investments were $23.334 million as of June 30, 2025.
Operational and liquidity highlights: the filing reports 100 active partners and 381 active programs, including 28 OmniAb-derived antibodies in clinical development, one under regulatory review, and three approved partner products. Management states existing cash, cash equivalents and short-term investments are sufficient to support operations for at least the next 12 months. The company recognized a $3.0 million gain from sale of an ion channel asset in Q2 2025.